Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols

Friday, July 27, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 27, 2018 /PRNewswire/ --

If you want a free Stock Review on EPZM,ESPR, EXEL, andGRFS sign up now

at https://stocktraderreport.com/registration/. On Thursday, July 26, 2018, the NASDAQ Composite closed the trading session at 7,852.18, down 1.01%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 25,527.07;
and the S&P 500 closed at 2,837.44, slightly dropping 0.30%. This Friday, StockTraderReport.com has released technical reports on the following Biotechnology stocks: Epizyme Inc. (NASDAQ: EPZM), Esperion Therapeutics Inc. (NASDAQ: ESPR), Exelixis Inc. (NASDAQ: EXEL), and Grifols S.A. (NASDAQ: GRFS). All you have to do is sign up today for this free limited time offer by clicking the link below. https://stocktraderreport.com/registration/

Epizyme

USA-based Epizyme Inc.'s stock finished Thursday's session 5.02% higher at $13.60 with a total trading volume of 672,193 shares, which is above its three months average volume of 434.97 thousand shares. The Company's shares have advanced 10.57% over the past twelve months. The stock is trading below its 50-day moving average by 10.06%. Additionally, shares of Epizyme, which discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the US, have a Relative Strength Index (RSI) of 45.92.

On July 03rd, 2018, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.

On July 19th, 2018, Epizyme announced plans to report its Q2 2018 financial results on August 02nd, 2018. Management will host a conference call and webcast that same morning at 8:30 a.m. ET to discuss these results and other business updates.A live webcast will be available under the investor section of the Company's website. Get the full research report on EPZM for free by clicking below at: https://stocktraderreport.com/registration/?symbol=EPZM

Esperion Therapeutics

On Thursday, shares in USA-headquartered Esperion Therapeutics Inc. recorded a trading volume of 439,248 shares. The stock ended the session 0.35% lower at $42.83. The Company's shares have advanced 11.94% in the last month. The stock is trading above its 50-day moving average by 5.95%. Moreover, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 56.73.

On July 11th, 2018, research firm Northland Capital downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Get access to our top-rated research, including the free report on ESPR at: https://stocktraderreport.com/registration/?symbol=ESPR

Exelixis

USA-headquartered Exelixis Inc.'s shares closed the day 3.04% higher at $21.69. The stock recorded a trading volume of 3.79 million shares. The Company's shares have gained 4.73% over the previous three months. The stock is trading above its 50-day moving average by 4.85%. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer, have an RSI of 58.16.

On July 17th, 2018, Exelixis announced that its Q2 2018 financial results will be released on August 01st, 2018, after the markets close. Management will host a conference call and webcast at 5:00 p.m. EDT that same day to discuss the results and provide a general business update. Access to the event is available on the Company's website. Click here to subscribe for a free membership which welcomes you with our report on EXEL at: https://stocktraderreport.com/registration/?symbol=EXEL

Grifols

Shares in Spain-based Grifols S.A. finished 1.03% higher at $21.49. The stock recorded a trading volume of 1.53 million shares, which is above its three months average volume of 1.00 million shares. The Company's shares have advanced 6.70% over the last twelve months. The stock is trading below its 50-day moving average by 3.22%. Furthermore, shares of Grifols, which develops, manufactures, and distributes biological medicines on plasma derived proteins in the US, Canada, Spain, rest of the European Union, and internationally, have an RSI of 50.61 and has a dividend yield of 2.14%. To get free access to your research report on GRFS, sign up at: https://stocktraderreport.com/registration/?symbol=GRFS

--

Stock Trader Report:

Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

STR has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stocktraderreport.com. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://stocktraderreport.com/privacy-policy/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stocktraderreport.com Phone number: 917-979-2038 Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE Stock Trader Report



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store